Benitec Biopharma Inc

For the period ended Jun 30, 2024. Filed Sep 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Sep 26, 2024

BNTC$9.87+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except par value and share amounts)

	June 30, 2024	June 30, 2023
Assets
Current assets:
Cash at bank	$50,866	$2,477
Restricted cash	63	13
Trade and other receivables	229	55
Prepaid and other assets	516	1,184
Total current assets	51,674	3,729
Property and equipment, net	179	87
Deposits	25	25
Prepaid and other assets	62	97
Right-of-use assets	270	526
Total assets	$52,210	$4,464
Liabilities and Stockholders’ Equity
Current liabilities:
Trade and other payables	$4,165	$3,231
Accrued employee benefits	475	472
Lease liabilities, current portion	284	275
Total current liabilities	4,924	3,978
Non-current accrued employee benefits	38
Lease liabilities, less current portion	—	284
Total liabilities	4,962	4,262
Commitments and contingencies (Note 12)
Stockholders’ equity:
Common stock, $0.0001 par value—160,000,000 shares authorized; 10,086,119 and 1,671,485 shares issued and outstanding at June 30, 2024 and 2023, respectively	1	—
Additional paid-in capital	238,398	168,921
Accumulated deficit	(190,259)	(167,889)
Accumulated other comprehensive loss	(892)	(830)
Total stockholders’ equity	47,248	202
Total liabilities and stockholders’ equity	$52,210	$4,464

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.